key: cord-0967942-183dnnru
authors: Kofteridis, Diamantis P.; Ioannou, Petros; Kondili, Eumorfia; Chamilos, Georgios; Filippatos, Theodosios D.
title: Personalized prophylactic anticoagulation in hospitalized patients with Covid-19 - The role of anti-Xa monitoring
date: 2021-04-29
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.04.024
sha: da23b9b9f60a95edda63ac47b72c79b7687f0d71
doc_id: 967942
cord_uid: 183dnnru

Due to the strong association between severe COVID-19 and a prothrombotic state, most experts suggest an intensified anticoagulation regimen, mostly including an intermediate dose of low-molecular heparin, even though there is no clear clinical evidence supporting the efficacy of this strategy. In our hospital, among 16 patients admitted due to COVID-19, initially treated with enoxaparin 40mg/daily, 81.3% needed dose adjustment due to lower than 0.4IU/ml anti-Xa levels. Based on this approach, a median enoxaparin dose of 60mg (IQR 50-80mg) once daily was needed to successfully tailor prophylaxis with an anti-Xa between 0.4-0.5IU/ml. A future randomized study comparing patients treated with prophylactic enoxaparin to patients treated with a tailored approach based on anti-Xa monitoring could be performed.

To the Editor, COVID-19 is a public health emergency. The last few months, there is increasing evidence of a strong association between severe COVID-19 and a prothrombotic state, which has been attributed to inflammatory immunopathology and endothelial inflammation [1] . We read with great interest two recent studies reporting on the prevalence of venous thromboembolism in patients with COVID-19 [2, 3] .

Interestingly, the prevalence of deep venous thrombosis (DVT) and pulmonary embolism (PE) is over 10% in almost all studies, implying that one of the primary therapeutic goals should be the implementation of adequate thromboprophylaxis in these patients. Accordingly, in a clinical vignette that was recently published in the New England Journal of Medicine, a clinical scenario of a patient hospitalized with severe COVID-19 is presented, and two different anticoagulation strategies are discussed [4] . Most experts suggest an intensified anticoagulation regimen, mostly including an intermediate dose of low-molecular heparin (e.g., enoxaparin, 0.5mg/kg twice daily), even though there is no clear clinical evidence supporting the efficacy of this strategy in patients with COVID-19, as was also recently shown in critically ill patients with COVID-19 [5] . Indeed, this intermediate dosing regimen of enoxaparin, which appears to be safe in patients with COVID-19, has been extrapolated from studies in trauma patients [6] .

Instead, anti-Xa monitoring of low molecular weight heparin is recommended for patients with renal dysfunction, severe obesity, or patients at high risk for thrombosis/bleeding. In our Department, we followed a protocol of an individualized prophylactic anticoagulation based on anti-Xa measurement.

Specifically, we used sequential anti-Xa measurement to tailor the dose of enoxaparin, aiming for anti-Xa levels of 0.4-0.5IU/ml (the higher tertile of prophylactic range).

J o u r n a l P r e -p r o o f

The unique characteristics of COVID-19 coagulopathy

Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and metaanalysis

Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management

Anticoagulation in Hospitalized Patients with Covid-19

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

Safety of intermediate dose of low molecular weight heparin in COVID-19 patients

Characteristics of patients hospitalized with COVID-19. COVID-19 patients (n=16)

Age (years), median (IQR) ratio, mmHg (IQR)

Maximum oxygen requirements (%FiO2), median (IQR)

Anti-Xa on enoxaparin 40mg od (IU/ml)

Duration of hospitalization (days), median (IQR)